Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific director transaction rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific increase in shareholding by a director following dividend reinvestment.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investors to Verify
- Transaction Type: Increase in ordinary shares via dividend reinvestment.
- Director Involved: Dr. M M Slaoui.
- Shares Acquired: 296 ordinary shares.
- Transaction Date: Notification received on October 15, 2012, relating to the dividend paid on October 4, 2012.
- Share Price: 1456 pence per share.